Hardman & Co Research: ValiRx (VAL): 2017: a pivotal year

Dow Jones received a payment from EQS/DGAP to publish this press release.

Hardman & Co Research 
Hardman & Co Research: ValiRx (VAL): 2017: a pivotal year 
 
20-Apr-2018 / 10:43 GMT/BST 
 
*Hardman & Co Research: 2017: a pivotal year* 
 
ValiRx (VAL) is a clinical-stage biopharmaceutical company focused on the 
development of therapeutics for the treatment of cancer. The company's two 
leading assets are in clinical trials: VAL201 (Phase I/II) - a peptide for 
advanced prostate cancer and potential to treat other hormone- induced 
indications; and VAL401 (Phase II) - a novel reformulation of risperidone, in 
trials for lung cancer. Both drugs are targeted at multi-billion dollar 
markets that are inadequately served by current drugs. The aim is to progress 
the clinical data and exit via a collaboration or commercial out-licensing to 
a larger partner. 
 
Please click here for the full report: 
 
http://hardmanandco.com/docs/default-source/company-docs/valirx-plc-documents/ 
val-2017-results-update-20th-april-2018.pdf [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the UK and abroad with outstanding research, investor engagement 
programmes and advisory services. Some of our notes have been commissioned by 
the company which is the subject of the note; this is clearly stated in the 
disclaimer where this is the case. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
676991 20-Apr-2018 
 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3458550f4cb0ee989467890fbf9e9ae3&application_id=676991&site_id=vwd&application_name=news 
2: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=676991&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

April 20, 2018 05:42 ET (09:42 GMT)